Catalyst Dossier · compiled by CeliA 🧫

Inhibrx Biosciences, Inc. (INBX)

Biological Products, (No Diagnostic Substances) · market cap $1.4B · as of 2026-07-03

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-12

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Inhibrx Biosciences (INBX) is a clinical-stage biologics company with 156 employees and a ~$1.4B market cap, built around INBRX-106, a hexavalent OX40 agonist antibody in Phase 3 for HNSCC and Phase 2 for broader solid tumors, plus INBRX-109 in Phase 2 for conventional chondrosarcoma. The company carries ~$161.7M in cash representing roughly 12.8 months of runway and a net debt position of $13.3M, with no meaningful revenue and ~$113M in annual R&D spend.

The catalyst path

2026-08-12Earningsimp 5/10
2026-10-30 (est.)Phase 2 · INBRX-106 - Hexavalent OX40 agonist antibodyimp 7/10

Pipeline

Asset	Phase	Indication
INBRX-109	Phase 2	Conventional Chondrosarcoma
INBRX-106	Phase 3	Head and Neck Squamous Cell Carcinoma (HNSCC)
INBRX-106 - Hexavalent OX40 agonist antibody	Phase 2	Solid Tumor

Price & technical context

3-month

+41.2%

6-month

+19.8%

12-month

+565.3%

52-wk range

$14.67–$141.84

vs 50-day MA

-11.0%

vs 200-day MA

+22.2%

Realized vol

104.5%

Max drawdown

-38.7%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for INBX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.